Trimurthi Ltd

Novelix Pharmaceuticals Ltd announced the appointment of Mr. Gnana Prakash Gattu as Whole Time Director for a period of 5 years, effective August 29, 2026. The approval was granted by the company's members at the 32nd Annual General Meeting held on September 30, 2026. Mr. Gattu, a graduate from IIT-Chennai, brings over 25 years of experience in management and information technology. He is not related to any existing directors but belongs to the promoter and promoter group of the company. He is not debarred from holding a director's office by any regulatory authority.

Novelix Pharmaceuticals Limited conducted its 32nd Annual General Meeting (AGM) on September 30, 2026, via Video Conferencing. The meeting successfully transacted business electronically, including the adoption of standalone financial statements for the year ended March 31, 2026. Shareholders approved the financial statements and re-appointed a director retiring by rotation. Additionally, Mr. Gnana Prakash Gattu was appointed as Whole Time Director. The company submitted the combined voting results and the consolidated scrutinizer's report as per SEBI regulations.

Novelix Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their relatives. This closure will be effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ended September 30, 2026. The company has directed all designated persons and insiders to refrain from trading in the company's securities during this period, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Novelix Pharmaceuticals Ltd has announced its 32nd Annual General Meeting (AGM) will be held on September 30, 2026, at 3:00 P.M. (IST) via Video Conferencing. In compliance with SEBI Listing Regulations, the company is providing shareholders whose email IDs are not registered with the company, a web-link to access the Annual Report for FY 2025-26 and the AGM notice on its website (www.novelixpharma.com). The company also detailed procedures for shareholders holding shares in physical and dematerialized modes to update their email addresses, KYC details, and dematerialize physical securities, referencing recent SEBI circulars.

Novelix Pharmaceuticals Ltd has submitted its annual report for the financial year ended March 31, 2026, in compliance with SEBI Listing Regulations. The report includes the notice for the 32nd Annual General Meeting (AGM) scheduled for September 30, 2026, to be held via Video Conferencing. The company, formerly Trimurti Limited, is undergoing a strategic transition into the pharmaceutical sector, focusing on innovation, quality, and sustainable growth. It aims to leverage its legacy to build a strong presence in the pharmaceutical industry, emphasizing quality-driven operations and solutions for evolving healthcare needs. The company is also sending web-links for accessing the AGM notice and annual report to members who have not registered their email IDs.

Novelix Pharmaceuticals Ltd has announced its 32nd Annual General Meeting (AGM) to be held on Wednesday, September 30, 2026, at 3:00 PM IST. The meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM). Key agenda items include the adoption of standalone financial statements for FY 2025-26, the appointment of a director retiring by rotation, and the special business of appointing Mr. Gnana Prakash Gattu as Whole Time Director for a term of five years. The company will also send a web-link for the AGM notice and Annual Report to members who have not registered their email IDs.

Novelix Pharmaceuticals Ltd has announced the date for its 32nd Annual General Meeting (AGM), scheduled for Wednesday, 30th September 2026, at 03:00 P.M. The meeting will be conducted via Video Conferencing/Other Audio Visual Means (OAVM). The company will close its Register of Members and Share Transfer Books from 24th September 2026 to 30th September 2026 for the AGM. The cut-off date for determining member eligibility for voting is set as 23rd September 2026. Remote e-voting will be open from 27th September 2026 (09:00 A.M.) to 29th September 2026 (05:00 P.M.).

Novelix Pharmaceuticals Ltd has announced the appointment of Mr. Gnana Prakash Gattu as a Whole-time Director for a period of five years, effective August 29, 2026. This appointment is subject to shareholder approval at the upcoming annual general meeting. Mr. Gattu, an IIT-Chennai graduate with over 25 years of experience in management and IT, is not related to any existing directors and belongs to the promoter group. He is not debarred from holding a director's office. The company was formerly known as Trimurthi Limited.

Novelix Pharmaceuticals Ltd announced the outcome of its board meeting held on August 29, 2026. The board approved the Board Report for the financial year ended March 31, 2026, and the Draft Notice for the Annual General Meeting (AGM). The 32nd AGM is scheduled for September 30, 2026, to be conducted via Video Conferencing/Other Audio Visual Means. The register of members and share transfer books will be closed from September 24 to September 30, 2026. M/s. Bharat Khaniwal & Co. has been appointed as the scrutinizer for e-voting. The cut-off date for electronic voting eligibility is September 23, 2026. Additionally, Gnana Prakash Gattu was appointed as Whole Time Director effective August 29, 2026.

Novelix Pharmaceuticals Ltd has announced a Board of Directors meeting scheduled for August 29, 2026. The agenda includes approving the notice for the 32nd Annual General Meeting (AGM), the Board Report for the financial year ended March 31, 2026, and appointing a scrutinizer for the AGM voting. Additionally, the board will consider the appointment of Mr. Gnana Prakash Gattu as Whole Time Director. The meeting will be held at the company's registered office.